PILOT STUDY OF INHALED NITRIC OXIDE IN PATIENTS WITH CYSTIC FIBROSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 一氧化氮（NO）在囊性纤维化（CF）患者的气道中减少。 吸入NO有可能成为CF肺病的有效治疗方法，特别是因为其抗炎和抗菌活性。 该初始项目的主要目的是评估在患有CF的较大儿童和成人中吸入NO超过2天的安全性和耐受性。 长期目标是确定吸入NO是否可能是CF患者急性肺部恶化期间的一种有用的治疗策略，甚至作为患有严重肺部疾病的CF患者的长期治疗方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nitric oxide (NO) is decreased in the airways of persons with cystic fibrosis (CF). Inhaled NO has the potential to be an effective treatment in CF lung disease, especially because of its anti-inflammatory and antimicrobial activities. The main objective of this initial project is to evaluate the safety and tolerability of inhaled NO over a 2 day period in older children and adults with CF. The long term objectives are to determine whether inhaled NO may be a useful therapeutic strategy for CF patients during an acute pulmonary exacerbation or even as a chronic therapy in CF patients with severe lung disease.